X

Drug Profile

TR 291144

Alternative Names: TR-290999; TR-291144; TRI-1144

Latest Information Update: 08 Nov 2010

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Trimeris
Class Peptides
Mechanism of Action HIV fusion inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
Available For Licensing Yes

Highest Development Phases

No development reported HIV infections

Most Recent Events

08 Nov 2010 TR 291144 is available for licensing as of 08 Aug 2008. http://www.trimeris.com/
16 Mar 2010 No development reported - Phase-I for HIV infections in USA (Parenteral)
05 Aug 2009 Monogram Biosciences has been acquired by Laboratory Corporation of America Holdings

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com